Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China.

Front Public Health · 2022 · PMC9730273 · PMID 36504948

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Impact of clinical benefit on reimbursement decisions The study shown that the difference in the magnitude of clinical benefits between drugs received positive and negative reimbursement decisions did not reach statistical significance (P riskbenefit − OS = 0.627, P riskbenefit − PFS = 0.087, P survivalbenefit − OS = 0.545, P survivalbenefit − PFS = 0.189).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.